1. Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2016.158
Figure 3 B‑cell involvement in the immunopathogenesis of SLE and relevant therapeutic targets
Figure 3 | B-cell involvement in the immunopathogenesis of SLE and relevant therapeutic targets. A key B-cell function is antigen presentation. Also, as B cells constitutively express both inhibitory and activating receptors, they can be simultaneously involved in immune activation as well as immunoregulatory functions (including their autoregulation by IL-10); the latter are independent of their antibody-dependent effector functions. By contrast, T cells can only upregulate inhibitory receptors after activation via antigen presentation. A number of potential therapeutic approaches target B cells, either via intrinsic B-cell functions or via their extrinsic interactions with other immune cells (Table 1 lists examples of targetable molecules). APC, antigen-presenting cell; GC, germinal centre; TFH, T follicular helper cell; TH1, T helper type 1 cell; TH17, T helper type 17 cell; BAFF-R, B-cell-activating factor receptor, also known as TNF receptor superfamily member 13C; TCR, T-cell receptor; BCR, B-cell receptor.
Dörner, T. & Lipsky, P. E. (2016) Beyond pan‑B‑cell-directed therapy — new avenues and insights into the pathogenesis of SLE
Nat. Rev. Rheumatol. doi: /nrrheum